"We ask that the Government finally adopt a policy of full transparency on drug costs and, therefore, undertake to ensure that AIFA does not enter into agreements with pharmaceutical lawsuits that include confidentiality clauses or any other element that may have opaque characteristics ”.
This is how the deputies of the 5 Star Movement summarize some of the requests contained in the resolution 'Transparency of the agreements entered into by AIFA with pharmaceutical companies', at first signature Silvia Giordano, which today began its process in the referent office.
“We also ask – added the deputies – that all the data held by AIFA be published on the decisions taken to authorize the marketing of drugs by the Agency's Price and Reimbursement Committee and the Scientific Technical Committee. We also ask - they add - that the law be finally respected directive 89/105/EEC which, among other things, provides that national agreements on the subject of prices of medical specialties are made public, including the way in which they operate in individual cases, and all the criteria on which they are based".
